• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

MGC Pharmaceuticals Shares Lift on Landmark UK Import Permit (ASX:MXC)

Like 0

By Kiryll Prakapenka, Tuesday, 14 September 2021

MGC Pharmaceuticals said this marks the first time an epilepsy treatment containing THC and still undergoing clinical trials was approved by UK authorities for import. The news saw MGC Pharmaceuticals [ASX:MXC] shares jump 10% at the time of writing.

The MGC Pharmaceuticals Ltd’s [ASX:MXC] CannEpil+ product to treat refractory epilepsy has been granted approval for UK import.

MGC Pharmaceuticals said this marks the first time an epilepsy treatment containing THC and still undergoing clinical trials was approved by UK authorities for import.

The news saw MGC Pharmaceuticals Ltd’s [ASX:MXC] shares jump 10% at the time of writing.

ASX MXC - MGC Share Price ChartSource: TradingView.com

MGC Pharma stock has climbed almost 160% in the last 12 months.

Despite the significant gain, the firm is still down from its 13-cent, 52-week peak.

The question now is whether today’s positive announcement can send MGC’s share price back to its prior highs.

Promising Small-Cap Stocks: Market expert Ryan Clarkson-Ledward reveals why these four undervalued stocks could potentially soar in 2021. Click here to learn more.

Landmark UK import permit granted for CannEpil+

CannEpil+, based on MGC’s CannEpil, is a phytocannabinoid treatment for refractory or drug-resistant epilepsy.

MXC announced today that CannEpil+ was approved for UK import by the Medicine and Healthcare products Regulatory Agency (MHRA).

CannEpil+ has also been approved for prescription for patients in the UK.

CannEpil+ will initially be used to treat 10 patients in the UK suffering from refractory epilepsy, with MGC Pharma providing CannEpil+ free of charge to these patients for six months.

This is the first time that UK authorities have approved an epilepsy treatment still on a clinical pathway (Phase IIB) containing tetrahydrocannabinol (THC).

Roby Zomer, Co-founder and Managing Director of MGC Pharma, said:

‘The approval for the import of CannEpil+ to the UK and the associated compassionate prescriptions is an important step towards our global roll out of the treatment, and our continued commitment to patients.

‘Achieving MHRA approval has been an ongoing process for some time with our UK partner Elite Pharmaco, and we expect the first patients in the UK to begin treat with CannEpil+ in the coming months.’

What next for MGC Pharma?

Today’s announcement follows MGC securing import approval in India for its proposed COVID-19 treatment as a final step in obtaining Emergency Use Authorisation for the treatment of patients with COVID‐19.

Last month, MGC also signed a US$24 million supply agreement with AMC Holdings for MGC phytomedicine products over three years, with a minimum of US$3 million within the first year.

These are positive developments, and it will be interesting to see whether they can spur momentum for the stock in the medium term.

Now MGC is just one firm in the emerging pot stock sector. If you’re interested in more pot stocks,

He discusses three promising pot stocks.

One is an innovative medicinal cannabis producer that helps patients with critical health conditions. Another is a global investment group that manages multiple cannabis-related ventures across the value chain. And the other is an exciting ETF that invests in established leaders within the cannabis industry.

It’s a great introduction to the sector.

Regards,

Kiryll Prakapenka,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The first place to look thanks to the US/China truce
    By Callum Newman

    My colleague Greg Canavan, a true contrarian, is positioning in a spread of energy companies to take advantage of the very investor disinterest and lack of supply growth I just described. We know, too, that one of Warren Buffett’s last moves was to load up on American energy. Personally, I prefer something more durable and permanent…

  • The trade war is over. Tax cut chaos is next.
    By Nick Hubble

    Trump isn’t just imposing tariffs. He also wants to cut taxes. If the tariff tantrum gave us a taste for how he’ll go negotiate, hold on tight!

  • The Untold Tariff Story
    By Callum Newman

    The real tariff story isn't what you're reading in the headlines. It's not about short-term market volatility or quarterly earnings impacts. The true story – and the massive investment opportunity – is about the fundamental restructuring of American manufacturing that's now underway. Trump's tariffs are accelerating AI adoption in American industry. Today, I want to show you the companies that are emerging as the backbone of this transformation.

Primary Sidebar

Latest Articles

  • The first place to look thanks to the US/China truce
  • The trade war is over. Tax cut chaos is next.
  • The Untold Tariff Story
  • The Big Payday: Chasing Profits in Risky Places
  • China’s plan to pop the AI bubble and sink Mag7 for good

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988